Antipsychotics and dietary interventions: Pharmacodynamics, pharmacokinetics, and synergisms in therapy.

IF 17.3 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Pharmacological Reviews Pub Date : 2025-07-01 Epub Date: 2025-04-29 DOI:10.1016/j.pharmr.2025.100061
Cristiana Perrotta, Carla Carnovale, Marco Pozzi, Clara De Palma, Davide Cervia, Maria Nobile, Emilio Clementi
{"title":"Antipsychotics and dietary interventions: Pharmacodynamics, pharmacokinetics, and synergisms in therapy.","authors":"Cristiana Perrotta, Carla Carnovale, Marco Pozzi, Clara De Palma, Davide Cervia, Maria Nobile, Emilio Clementi","doi":"10.1016/j.pharmr.2025.100061","DOIUrl":null,"url":null,"abstract":"<p><p>Antipsychotic (AP) medications are the primary treatment for severe mental illnesses, including schizophrenia and severe mood disorders. APs are currently categorized into typical or first-generation APs and atypical or second-generation APs. Although both first-generation and second-generation APs are considered effective in treating psychotic symptoms in severe mental disorders, they differ in their mechanisms, treatment strategies, and side effect profiles. Because of their potential motor and metabolic side effects, which often compromise patient adherence and clinical outcomes, whether and how to use APs remains controversial. The use of dietary interventions in combination with APs is emerging as a viable strategy to reduce AP adverse effects while maintaining their efficacy and enhance patient adherence to treatment. In contrast to drugs that possess a well defined molecular mechanism of action, dietary interventions act in pleiotropic ways by nature. While providing a holistic approach to patient care this pleiotropy needs to be analyzed and systematized to enhance the efficacy and safety of the combination of them with APs. Guidelines for this type of treatment are still needed. In this review, we explore the pharmacological properties, therapeutic applications, and limitations of APs, and discuss the potential benefits and limitations of those dietary interventions that are employed to improve the efficacy and counteract side effects of APs discussing also their mechanisms of action. Finally, we critically discuss the main results of clinical studies combining APs and dietary interventions and provide a view on future directions in terms of research and clinical use of these combinations. SIGNIFICANCE STATEMENT: Antipsychotic drugs are useful in a variety of psychiatric conditions, yet their use is hampered by issues of efficacy and safety. An important step toward therapy optimization is their use in combination with dietary interventions (ie, dietary supplements and nutraceuticals) that have shown promising results in clinical trials.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"77 4","pages":"100061"},"PeriodicalIF":17.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pharmr.2025.100061","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Antipsychotic (AP) medications are the primary treatment for severe mental illnesses, including schizophrenia and severe mood disorders. APs are currently categorized into typical or first-generation APs and atypical or second-generation APs. Although both first-generation and second-generation APs are considered effective in treating psychotic symptoms in severe mental disorders, they differ in their mechanisms, treatment strategies, and side effect profiles. Because of their potential motor and metabolic side effects, which often compromise patient adherence and clinical outcomes, whether and how to use APs remains controversial. The use of dietary interventions in combination with APs is emerging as a viable strategy to reduce AP adverse effects while maintaining their efficacy and enhance patient adherence to treatment. In contrast to drugs that possess a well defined molecular mechanism of action, dietary interventions act in pleiotropic ways by nature. While providing a holistic approach to patient care this pleiotropy needs to be analyzed and systematized to enhance the efficacy and safety of the combination of them with APs. Guidelines for this type of treatment are still needed. In this review, we explore the pharmacological properties, therapeutic applications, and limitations of APs, and discuss the potential benefits and limitations of those dietary interventions that are employed to improve the efficacy and counteract side effects of APs discussing also their mechanisms of action. Finally, we critically discuss the main results of clinical studies combining APs and dietary interventions and provide a view on future directions in terms of research and clinical use of these combinations. SIGNIFICANCE STATEMENT: Antipsychotic drugs are useful in a variety of psychiatric conditions, yet their use is hampered by issues of efficacy and safety. An important step toward therapy optimization is their use in combination with dietary interventions (ie, dietary supplements and nutraceuticals) that have shown promising results in clinical trials.

抗精神病药物和饮食干预:药效学、药代动力学和治疗中的协同作用。
抗精神病药物是严重精神疾病的主要治疗方法,包括精神分裂症和严重情绪障碍。目前,ap分为典型的第一代ap和非典型的第二代ap。虽然第一代和第二代ap都被认为对治疗严重精神障碍的精神病症状有效,但它们在机制、治疗策略和副作用方面存在差异。由于其潜在的运动和代谢副作用,往往会损害患者的依从性和临床结果,是否以及如何使用APs仍然存在争议。饮食干预与AP联合使用正在成为一种可行的策略,以减少AP的不良反应,同时保持其疗效并提高患者对治疗的依从性。与具有明确的分子作用机制的药物不同,饮食干预在本质上以多效性的方式起作用。在为患者提供整体护理方法的同时,需要对这种多效性进行分析和系统化,以提高它们与ap联合使用的有效性和安全性。这类治疗的指导方针仍然需要。在这篇综述中,我们探讨了白蛋白的药理学特性、治疗应用和局限性,并讨论了那些用于提高白蛋白疗效和抵消其副作用的饮食干预的潜在益处和局限性,并讨论了它们的作用机制。最后,我们批判性地讨论了将ap与饮食干预相结合的临床研究的主要结果,并对这些组合的研究和临床应用的未来方向提出了看法。意义声明:抗精神病药物对多种精神疾病有效,但其使用受到有效性和安全性问题的阻碍。优化治疗的重要一步是将它们与饮食干预(即膳食补充剂和营养保健品)结合使用,在临床试验中显示出有希望的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacological Reviews
Pharmacological Reviews 医学-药学
CiteScore
34.70
自引率
0.50%
发文量
40
期刊介绍: Pharmacological Reviews is a highly popular and well-received journal that has a long and rich history of success. It was first published in 1949 and is currently published bimonthly online by the American Society for Pharmacology and Experimental Therapeutics. The journal is indexed or abstracted by various databases, including Biological Abstracts, BIOSIS Previews Database, Biosciences Information Service, Current Contents/Life Sciences, EMBASE/Excerpta Medica, Index Medicus, Index to Scientific Reviews, Medical Documentation Service, Reference Update, Research Alerts, Science Citation Index, and SciSearch. Pharmacological Reviews offers comprehensive reviews of new pharmacological fields and is able to stay up-to-date with published content. Overall, it is highly regarded by scholars.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信